pmd20221231_10k.htm

0001171843-23-002005.txt : 20230330 0001171843-23-002005.hdr.sgml : 20230330 20230330171535 ACCESSION NUMBER: 0001171843-23-002005 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230330 DATE AS OF CHANGE: 20230330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSYCHEMEDICS CORP CENTRAL INDEX KEY: 0000806517 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 581701987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-13738 FILM NUMBER: 23781764 BUSINESS ADDRESS: STREET 1: 125 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-206-8220 MAIL ADDRESS: STREET 1: 125 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 10-K/A 1 pmd20230329_10ka.htm FORM 10-K/A pmd20221231_10k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K/A

Amendment No. 1

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-13738

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware	58-1701987
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

289 Great Road Acton, Massachusetts	01720
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number Including Area Code: (978) 206-8220

Securities registered pursuant to Section 12(b) of the Act:

Title of Class	Trading Symbol(s)	Name of each exchange on which registered
Common stock. $0.005 par value	PMD	The Nasdaq Stock Market, LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by a check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Exchange Act of 1934). Yes ☐ No ☒

Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934). Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See definitions of “accelerated filer”, “large accelerated filer”, “non-accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934.

Large Accelerated Filer ☐	Accelerated Filer ☐	Non-Accelerated Filer ☒
Smaller Reporting Company ☒	Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities and Exchange Act of 1934). Yes ☐ No ☒

As of June 30, 2022, there were 5,626,196 shares of Common Stock of the Registrant outstanding. The aggregate market value of the Common Stock of the Registrant held by non-affiliates (assuming for these purposes, but not conceding, that all executive officers, directors and 5% shareholders are “affiliates” of the Registrant) as of June 30, 2022, was $26.9 million, computed based upon the closing price of $6.34 per share on June 30, 2022.

As of March 15, 2023, there were 5,684,647 shares of Common Stock of the Registrant outstanding.

Auditor Info:

Name – BDO USA, LLP

Location – Boston, Massachusetts

PCAOB Number - 243

EXPLANATORY NOTE

On March 27, 2023 Psychemedics Corporation (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Original Form 10-K”). This Amendment No. 1 (the “Amendment”) amends Part II, Item 9B to correct an error in the description of the Change in Control Severance Agreement entered into on March 21, 2023 with Charles Doucot. It also amends Part III - EXECUTIVE COMPENSATION – Potential Payments upon Termination and Change in Control - to reflect a correction of amounts payable to Mr. Doucot.

Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, we have repeated in this Amendment the entire text of Item 9B of Part II and Part III - EXECUTIVE COMPENSATION – Potential Payments upon Termination and Change in Control - of the Original Filing in this Amendment and we have also repeated Part IV Item 15, Exhibits, Financial Statement Schedules in its entirety.

In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and our principal financial officer are filed as exhibits to this Amendment under Item 15 of Part IV hereof.

Except as stated herein, this Amendment does not reflect events occurring after the filing of the Original Form 10-K with the Securities and Exchange Commission on March 27, 2023 and no attempt has been made in this Amendment to modify or update other disclosures as presented in the Original Form 10-K.

Item 9B. Other Information

On March 21, 2023, the Board established August 17, 2023, as the scheduled date of the Company’s 2023 annual meeting of stockholders (the “2023 Annual Meeting”). TheCompany will publish additional details regarding the 2023 Annual Meeting, including its record date and the exact time, location and matters to be voted on at the 2023 Annual Meeting, in the Company’s proxy statement for the 2023 Annual Meeting when it is filed, which the Company currently expects will be in late June 2023.

On March 21, 2023, the Company entered into a new change in control severance agreement with Raymond C. Kubacki, Chairman, Chief Executive and President. The agreement runs until May 2, 2024. It provides that if, during the term, the Company terminates the employee’s employment for any reason other than for Cause (as defined in the agreement), death or disability (as defined in the agreement) or if the employee terminates his employment for Good Reason (as defined below), in either case, within twelve months following a Change in Control (as defined in the agreement), he will be entitled to receive a continuation of base salary for a period of up to twelve months from the date of such termination, except that Good Reason termination solely on account of a change in location would give rise to a continuation of base salary for a period of up to six months rather than twelve months. Good Reason includes a change in title, a reduction in base salary then in effect, a material decrease in duties or responsibilities, or a change of location. The agreement also prohibits the employee from working for a competitor of the Company or from soliciting employees of the Company during the period he is eligible to receive salary continuation under the agreement. Mr. Kubacki’s agreement was in replacement of an agreement executed in 2018, which had a five-year term and expired in February 2023.

On March 21, 2023, the Company also entered into a new change in control severance agreement with Charles Doucot, Executive Vice President. The agreement runs until May 2, 2026. It provides that if, during the term, the Company terminates the employee’s employment for any reason other than for Cause (as defined in the agreement), death or disability (as defined in the agreement) or if the employee terminates his employment for Good Reason (as defined below), in either case, within twelve months following a Change in Control (as defined in the agreement), he will be entitled to receive a continuation of base salary for a period of up to twelve months from the date of such termination at a rate equal to the greater of his then current rate, or the rate in effect on August 1, 2020. Good Reason includes a change in title, a reduction in base salary then in effect, or a material decrease in duties or responsibilities. The agreement also prohibits the employee from working for a competitor of the Company or from soliciting employees of the Company during the period he is eligible to receive salary continuation under the agreement. Mr. Doucot’s agreement supersedes the agreement executed in 2018, as amended which had a five-year term and was due to expire in May, 2023.

The foregoing summaries of the change in control severance agreements with Mr. Kubacki and Mr. Doucot do not purport to be complete and are qualified in their entirety by reference to the change in control severance agreements with them which are attached hereto as Exhibits 10.9 and 10.11 and incorporated by reference into this report.

PART III

EXECUTIVE COMPENSATION

Potential Payments upon Termination and Change in Control

The Company has change-in-control severance agreements in place with each of Messrs. Kubacki and Doucot providing for severance benefits for a period of up to 12 months in the event of termination within 12 months following a change in control (as defined in the agreements). The agreements provide for severance benefits only if (1) the Company undergoes a change in control (as defined in the agreement) and (2) within 12 months thereafter either (a) the Company (or its successor) terminates the employee (other than termination for “cause”), or (b) the employee terminates his employment for “good reason” (as defined in his agreement). The agreements do not provide for severance benefits in the event of an employee’s death or disability, or in the event of his voluntary termination without good reason. The agreements provide that the employee shall not compete with the Company during the period in which he is entitled to receive severance payments. Except for such change-in-control severance agreements, and except for the separate employment severance agreement with Mr. Doucot described below, none of the named executive officers has an employment agreement with the Company.

Each of the stock unit award and option agreements with Messrs. Kubacki, Doucot and Schaffer described in the Summary Compensation Table above provides that the vesting would accelerate upon a change in control. In the event the Company had incurred a change in control on December 31, 2022, and terminated the employment of Messrs. Kubacki, Doucot and Schaffer on such date, the amounts paid out to such named executive officers under: (i) the Change in Control agreements with Messrs. Kubacki and Doucot in effect on the date of filing this Report and (ii) the existing equity award agreements with Messrs. Kubacki, Doucot and Schaffer, would have been as follows:

Payments and Benefits Upon Termination and Change in Control

(a)	(b)		(c)		(d)		(e)		(f)
Name	Salary⁽¹⁾		Accrued Vacation⁽²⁾		Health Benefits ⁽³⁾		Acceleration of Equity Awards⁽⁴⁾		Total
Raymond C. Kubacki ⁽⁵⁾
12 Month	$	486,500	$	18,718	$	33,325	$	268,275	$	806,818
6 Month (change of location only)	$	243,250	$	18,718	$	16,663	$	268,275	$	546,906
Charles Doucot ⁽⁶⁾
12 Month	$	340,000	$	11,489	$	29,136	$	142,100	$	522,725
Michael I. Schaffer
12 Month	$	-	$	11,764	$	-	$	58,188	$	69,952

(1)	The amounts in column (b) reflect current base salary in effect on December 31, 2022 for Mr. Kubacki and on August 1, 2020 for Mr. Doucot.
(2)	Accrued vacation is payable upon separation of service whether or not in connection with a change in control.
(3)	The amounts in column (d) represent the amount payable by the Company during the applicable period for continuation of health benefits.
(4)	The amounts in column (e) reflect: (i) the acceleration of the vesting under stock unit awards granted under the Company’s 2006 Incentive Plan triggered by a change in control, as provided in each executive officer’s respective stock unit award agreement with the Company, the valuation of which is determined by multiplying the number of stock unit awards that would have become vested on December 31, 2022, pursuant to such acceleration provision, times the closing price of the Company stock on such date ($4.90 per share); plus (ii) the acceleration of the vesting under in-the-money unvested stock options granted under the Company’s 2006 Incentive Plan triggered by a change in control, as provided in each executive officer’s respective stock option agreement with the Company, the valuation of which is determined by assuming a net exercise of all unvested stock options having an exercise price that is less than the closing price of the Company stock on such date ($4.90 per share).
(5)	Mr. Kubacki’s arrangement provides for up to 12 months of salary in the event of a termination by the Company without cause (as defined in his agreement) or a termination by him for good reason (as defined in his agreement) in either case, within a 12 month period following a change in control of the Company (as such term is defined in the agreement), provided, however, that in the event of termination by Mr. Kubacki for good reason solely on account of a change in his required place of employment, following a change in control, then in lieu of 12 months of salary and bonus compensation, his benefits would be limited up to 6 months of salary and bonus compensation.
(6)	Mr. Doucot’s arrangement provides for 12 months of salary (at the rate that was in effect on August 1, 2020, or any higher rate thereafter in effect), in the event of a termination by the Company without cause (as defined in his agreement) or a termination by him for good reason (as defined in his agreement) in either case, within a 12 month period following a change in control of the Company (as such term is defined in the agreement).

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a) (3) See “Exhibit Index” included elsewhere in this Report.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PSYCHEMEDICS CORPORATION

Date: March 30, 2023	By:/s/ RAYMOND C. KUBACKI Raymond C. Kubacki Chairman, President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.


/s/ RAYMOND C. KUBACKI Raymond C. Kubacki	Chairman, President and Chief Executive Officer, Director (Principal Executive Officer)	March 30, 2023

/s/ WILLIAM B. NORRIS William B. Norris	Controller (Principal Financial and Accounting Officer)	March 30, 2023

PETER H. KAMIN* Peter H. Kamin	Director

DARIUS G. NEVIN* Darius G. Nevin	Director

ANDREW M. REYNOLDS* Andrew M. Reynolds	Director

FRED J. WEINERT* Fred J. Weinert	Director

ROBYN C. DAVIS* Robyn C. Davis	Director

*By: /s/ RAYMOND C. KUBACKI Raymond C. Kubacki	Attorney-in-Fact	March 30, 2023

EXHIBIT INDEX


Exhibit Number		Description
3.1		Amended and Restated Certificate of Incorporation filed with the State of Delaware on August 1, 2002 — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2002).
3.2		Amended and Restated By-Laws of the Company — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on July 31, 2015).
4.1		Specimen Stock Certificate — (Incorporated by reference from the Registrant’s Registration Statement on Form 8-A filed on July 31, 2002).
10.2.1P		Lease dated October 6, 1992, with Mitchell H. Hersch, et. Al with respect to premises in Culver City, California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 1992).
10.2.2P		Security Agreement dated October 6, 1992, with Mitchell H. Hersch et. Al — (Incorporated by reference from the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 1992).
10.2.3		First Amendment to Lease dated with Mitchell H. Hersch, et.al California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).
10.2.4		Second Amendment to Lease dated with Mitchell H. Hersch, et.al. California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).
10.2.5		Third Amendment to Lease dated December 31, 1997, with Mitchell H. Hersch, et.al. California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).
10.2.6		Fourth Amendment to Lease dated May 24, 2005, with Mitchell H. Hersch, et.al. California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005).
10.2.7		Sixth Amendment to Lease dated October 13, 2015, with Mitchell H. Hersch, et.al. California — Supersedes the Fifth amendment in its entirety (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015)
10.2.8		Eighth Amendment to Lease dated March 20, 2022, with Mitchell H. Hersch, et.al. California — Supersedes the Seventh amendment in its entirety. (1)

TABLE OF CONTENTS


Exhibit Number		Description
10.3*		2006 Incentive Plan, as amended — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 17, 2021).
10.4*		Form of Stock Unit Award used with employees and consultants under the 2006 Incentive Plan — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016).
10.5*		Form of Stock Unit Award used with non-employee directors under the 2006 Equity Incentive Plan — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016).
10.6*		Form of Incentive Stock Option Agreement used with employees under the 2006 Incentive Plan (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016)
10.7*		Form of Non Qualified Stock Option Agreement used with employees and consultants under the 2006 Incentive Plan (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016)
10.8*		Form of Non Qualified Stock Option Agreement used with non-employee directors under the 2006 Incentive Plan (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016)
10.9*		Change in control severance agreement with Ray Kubacki dated March 21, 2023 (1)
10.10*		Severance agreement with Charles Doucot dated February 26, 2019 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)
10.11*		Change in Control Severance agreement with Charles Doucot dated March 21, 2023 (2)
10.12		Lease dated July 29, 2019, with Culver City/Hannum, LLC with respect to 5750 Hannum premises in Culver City, CA — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019)
10.13		Loan agreement dated March 20, 2014, with Banc of America Leasing and Capital, LLC — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014)
10.13.1		Letter Agreement dated September 15, 2015, with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated September 15, 2015 and Proposal Letter dated August 19, 2015 — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015)
10.13.2		Letter Agreement dated October 30, 2017, with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated November 10, 2017 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017)
10.13.3		Letter Agreement dated December 3, 2019, with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated December 4, 2019 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)
10.13.4		Conditional Waiver and Amendment No 1. To Master Loan and Security Agreement dated November 4, 2020, with Banc of America Leasing & Capital, LLC — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on November 9, 2020)
10.13.5		Conditional Waiver dated March 19, 2021, and Amendment Number 002 dated March 23, 2021 to Master Loan and Security Agreement Amendment dated March 19, 2014 between Banc of America Leasing & Capital, LLC and Psychemedics Corporation LLC — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on March 23, 2021)
10.14		Form of Indemnification Agreement with Directors and Executive Officers of the Company* (1)

21.1		Subsidiaries of the Registrant (1)
23.1		Consent of BDO USA, LLP, Independent Registered Public Accounting Firm (1)
24		Power of Attorney (1)
31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (2)
31.2		Certification of Controller Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (2)
32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)
32.2		Certification of Controller Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)

101.INS		Inline XBRL Instance Document (1)
101.SCH		Inline XBRL Taxonomy Extension Schema (1)
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase (1)
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase (1)
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase (1)
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase (1)
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) (1)

*	Management compensation plan or arrangement

P	Indicates a filing submitted in paper

(1)	Previously filed with our Original Form 10-K

(2)	Filed with this Amendment No. 1 to Annual Report on Form 10-K/A

EX-10.11 2 ex_495196.htm EXHIBIT 10.11 ex_495196.htm

Exhibit 10.11

March 21, 2023

CONFIDENTIAL

Charles Doucot

c/o Psychemedics Corporation

289 Great Road

Acton, MA 01720

Dear Charlie:

This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14.

If at any time after the effective date hereof and prior to May 2, 2026, your employment is terminated by the Company without Cause, or you voluntarily terminate your employment for Good Reason, in either case at the time of or within twelve (12) months following a Change of Control of the Company, then you will continue to be paid monthly for a period of twelve (12) months following the date of such termination.an amount (“Termination Pay”) equal to one-twelfth of the greater of: (I) your annual base salary in effect immediately prior to such termination; or (ii) your annual base salary in effect on August 1, 2020. The Company agrees to continue to make health insurance available to you, under such health insurance plan as the Company has in effect, for so long as you are receiving Termination Pay and so long as you contribute such portion of the premiums for such insurance as is required of employees under such plan. You agree, however, that if you obtain health insurance coverage through another employer while you are eligible to receive health insurance under this Agreement, the Company shall no longer be required to make health insurance available to you under this Agreement. You agree to give the Company at least fourteen (14) days prior written notice of the termination of your employment in the event of your voluntary termination without Good Reason. You shall not be entitled to Termination Pay as a result of termination by reason of your death or Disability following a Change of Control of the Company.

Notwithstanding any other provision of this Agreement, the Termination Pay contemplated to be paid to you under certain circumstances set forth in this Agreement shall only be paid in consideration of the execution and delivery by you of a release reasonably satisfactory to the Company waiving all claims you, your heirs, or legal representatives have or may have against the Company or any of its shareholders, officers, directors, employees or agents with respect to your employment or the termination thereof, or any other claim.

Charles Doucot

March 21, 2023

Page 2

You acknowledge that as the Company’s Executive Vice President, you are in possession of specialized information concerning the total operations, conduct, management, and strategy of the Company, as well as proprietary information concerning the Company’s products and services and that the applicability of your knowledge of these matters is applicable to all geographic areas in which the Company does business. You further acknowledge that the Company has a legitimate business interest in protecting its hair testing business from unfair competition.

In addition to any other confidentiality obligations you may have as an employee of the Company, you shall not, without the prior and express written approval of the Company, either during or subsequent to the term of your employment, disclose or use or enable another to disclose or use any secret, private or confidential information, trade secret or other proprietary knowledge of the Company, or its subsidiaries, divisions, employees or agents. Upon termination of your employment with the Company, you shall deliver to the Company all equipment, records and copies of records, notes, data, memoranda, prototypes, designs, customer lists and other information which is embodied in physical media and documents belonging to the Company which are then in your possession. You agree that all such information and documents shall be the property of the Company and that the obligations set forth in this paragraph shall survive termination of your employment.

You agree that in addition to any other covenant not to compete with the Company following termination of your employment to which you may be bound, if you or the Company shall terminate your employment in such a manner as to entitle you to Termination Pay under paragraph 1 above, you shall not, for so long as you are entitled to receive such Termination Pay:

(a) directly or indirectly own, manage, operate or control, or participate in the ownership, management, operation or control of, or become associated in any capacity with any business enterprise, firm, corporation or company related to the field of testing for the detection of drug use, which is in competition with the business of the Company, or directly or indirectly accept employment with or render services on behalf of a competitor of the Company, or any other third party, in any capacity which may reasonably be considered to be useful to the competitor or such other third party to become a competitor, without receiving the Company’s prior written approval; or

Charles Doucot

March 21, 2023

Page 3

(b) induce or attempt to induce any employee, officer, consultant, or agent of the Company to leave the employ thereof or in any way interfere with the relationship between the Company and any employee, officer, consultant, or agent thereof; hire directly or through another entity any person who was an employee of the Company at any time during the six (6) months prior to the date such person is to be so hired; or induce or attempt to induce any customer, client, supplier, licensee, or other business relation of the Company to cease doing business with the Company or in any way interfere with the relationship between any such customer, client, supplier, licensee, or business relation and the Company (including, without limitation, making any negative statements or communications concerning the Company).

You agree that your obligations under paragraphs 4 and 5 are special, unique, and extraordinary and that any breach by you of such obligations shall be deemed material, and shall be deemed to cause irreparable injury not properly compensable by damages in an action at law, and the rights and remedies of the Company under paragraphs 4 and 5 may, therefore, be enforced both at law and in equity, by injunction or otherwise. For purposes of paragraphs 4 and 5, the term “Company” shall include any and all subsidiaries or divisions of the Company.

The 3-year period set forth in paragraph 1 above may be extended only with the mutual written agreement of the parties.

If at any time a controversy between you and the Company arises as to the meaning or operation of this Agreement, such controversy shall be submitted to arbitration by either party in Boston, Massachusetts, before an arbitrator to be named by the President of the Boston Branch of the American Arbitration Association, provided however, that the Company shall also have the rights set forth in paragraph 6 above. Such arbitration proceedings shall be conducted in accordance with the rules and procedures then in effect of the American Arbitration Association. The decision of the arbitrator shall be binding upon the parties and judgment on any award made by the arbitrator may be entered in any court having jurisdiction thereof. The costs of the arbitrator shall be borne equally by you and the Company. Each party will bear his or its own legal costs.

This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts without reference to principles of conflict of laws.

10.

This Agreement contains the entire agreement of the parties in respect of this transaction and supersede any prior agreement or understanding relating to your employment by the Company. Without limitation of the foregoing, your change in control severance agreement dated May, 2, 2018, as amended, is hereby terminated and of no further force or effect. No amendment or modification of any provision of this Agreement will be valid unless in writing signed by both parties. Any waiver must be in writing and signed by you or an authorized officer of the Company, as the case may be.

Charles Doucot

March 21, 2023

Page 4

11.

This Agreement shall be binding upon and inure to the benefit of:

(a) the Company, and any successors or assigns of the Company, whether by way of a merger or consolidation, or liquidation of the Company, or by way of the Company selling all or substantially all of the assets and business of the Company to a successor entity; and, subject to the Company's right to terminate your employment at any time, the Company agrees to require any successor entity to expressly assume or unconditionally guarantee the Company's obligations under this Agreement (unless such obligations are assumed by operation of law); and (b) you and your heirs, executors and administrators.

12.

Any notice or other communication required hereunder shall be in writing, shall be deemed to have been given and received when delivered in person, or, if mailed, shall be deemed to have been given when deposited in the United States mail, first class, registered or certified, return receipt requested, with proper postage prepaid, and shall be deemed to have been received on the third business day thereafter, and shall be addressed as follows:

If to the Company, addressed to:

Psychemedics Corporation

289 Great Road

Suite 200

Acton, MA 01720

Attn: President

If to you, addressed to:

Charles Doucot

c/o Psychemedics Corporation

289 Great Road

Suite 200

Acton, MA 01720

or such other address as to which any party hereto may have notified the other in writing.

Charles Doucot

March 21, 2023

Page 5

13.

Section 409A.

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (the “Code”), following a Change in Control of the Company, you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement would be considered deferred compensation subject to the twenty percent (20%) additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six (6) months and one (1) day after your separation from service, or (ii) your death.

(b) This Agreement is intended to be in compliance with the provisions of Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with said Section. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

(c) Solely for the purposes of Section 409A of the Code, each installment payment of Termination Pay shall be considered a separate payment.

(d) The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, said Section.

Charles Doucot

March 21, 2023

Page 6

14.

Definitions.

(a)“ Cause” shall mean: (i) theft or embezzlement, or attempted theft or embezzlement, by you of money or property of the Company, your perpetration or attempted perpetration of fraud, or your participation in a fraud or attempted fraud upon the Company; (ii) your unauthorized appropriation of, or attempt to misappropriate, any tangible or intangible assets or property of the Company, or your appropriation of, or attempt to appropriate, a business opportunity of the Company, including but not limited to attempting to secure or securing any profit for yourself or any of your family members or personal associates in connection with any transaction entered into on behalf of the Company; (iii) any act or acts of disloyalty, misconduct, or moral turpitude by you, including but not limited to violation of the Company’s sexual harassment or non-harassment policy, any of which the Board of Directors of the Company determines in good faith has been or is likely to be materially injurious to the interest, property, operations, business, or reputation of the Company, or its directors, employees or shareholders; (iv) any act or omission constituting gross negligence in connection with the performance of your duties on behalf of the Company which is materially injurious to the interest, property, operations, business, or reputation of the Company; (v) your conviction of a crime other than minor traffic violations or other similar minor offenses (including pleading guilty or entering a plea of no contest), or your indictment for a felony or its equivalent, or your being charged with a violent crime, a crime involving moral turpitude, or any other crime for which imprisonment is a possible punishment; (vi) your willful refusal or material failure (other than by reason of Disability) to carry out reasonable and lawful instructions and directives from the Board of Directors and your failure to cure or correct such refusal or failure within ten (10) days after receiving written notice from the Board of Directors describing such refusal or failure; or (vii) the material breach by you of your obligations under paragraphs 4 or 5 hereof or under any other confidentiality, non-compete, non-solicitation, non-disparagement or similar agreement with the Company.

(b)“ Change in Control of the Company” shall mean

(i) any person or group as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the “Exchange Act”) shall own more than 30% of the then outstanding shares of the outstanding Common Stock of the Company; or

(ii) the consummation of a reorganization, merger or consolidation or sale or disposition of all or substantially all of the assets of the Company (a “Business Combination”), unless, in each case following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners of the Common Stock of the Company immediately before the consummation of such Business Combination beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation that as a result of the transaction owns the Company or all or substantially all of the assets of the Company either directly or indirectly through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Common Stock of the Company; and (B) no person or group (as defined in Section 13(d) of the Exchange Act) of the Company or the corporation resulting from the Business Combination) beneficially owns, directly or indirectly, more than 30% of the then outstanding shares of the common stock of the corporation resulting from the Business Combination or of the combined voting power of the then outstanding voting securities of the corporation; or

Charles Doucot

March 21, 2023

Page 7

(iii) Individuals who, as of the date of this Agreement, constitute the Board of Directors of the Company (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board of Directors of the Company, provided, however, that any individual's becoming a director after the date of this Agreement whose election, or nomination for election by the stockholders of the Company, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board will be considered as though the individual were a member of the Incumbent Board, but excluding, for this purpose, any individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.

(c)“ Disability” shall mean your inability because of physical or mental incapacity to perform your usual duties at the Company for a period of one hundred eighty (180) days in any consecutive twelve (12) month period.

(d)“ Good Reason” shall mean: (i) reduction in your base salary below $298,700 or such higher base salary as is in effect immediately prior to such reduction; or (ii) a material decrease in your duties or responsibilities.

Charles Doucot

March 21, 2023

Page 8

If this letter correctly sets forth our understanding and agreement, please indicate your acceptance by signing both copies of this letter and returning one copy.

	Very truly yours,

	PSYCHEMEDICS CORPORATION


	By:	/s/ Raymond C. Kubacki
		Raymond C. Kubacki, President

Agreed to: March 21, 2023

/s/ Charles Doucot

Charles Doucot

EX-31.1 3 ex_494493.htm EXHIBIT 31.1 HTML Editor

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Raymond C. Kubacki, certify that:

1.	I have reviewed this First Amendment to Annual Report on Form 10-K/A of Psychemedics Corporation (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 30, 2023

By:	/s/ Raymond C. Kubacki
	Raymond C. Kubacki
	President and Chief Executive Officer
	(principal executive officer)

EX-31.2 4 ex_494494.htm EXHIBIT 31.2 HTML Editor

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, William B. Norris, certify that:

1.	I have reviewed this First Amendment to Annual Report on Form 10-K/A of Psychemedics Corporation (the “registrant”);

3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 30, 2023

By:	/s/ William B. Norris
	William B. Norris
	Controller
	(principal financial and accounting officer)

EX-101.SCH 5 pmd-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 6 pmd-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 pmd-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Annual Report Document, Period End Date Current Fiscal Year End Date Document, Fiscal Period Focus Document, Fiscal Year Focus Document, Transition Report Entity, File Number Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Well-known Seasoned Issuer Entity, Voluntary Filers Entity, Current Reporting Status Entity, Interactive Data, Current Entity, Filer Category Entity, Small Business Entity, Emerging Growth Company ICFR Auditor Attestation Flag Entity, Shell Company Entity, Public Float Entity, Common Stock Shares, Outstanding Auditor Name Auditor Location Auditor Firm ID Amendment Description Amendment Flag Entity, Central Index Key EX-101.PRE 8 pmd-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity, Registrant Name	PSYCHEMEDICS CORPORATION
Document, Type	10-K/A
Document, Annual Report	true
Document, Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document, Fiscal Period Focus	FY
Document, Fiscal Year Focus	2022
Document, Transition Report	false
Entity, File Number	1-13738
Entity, Incorporation, State or Country Code	DE
Entity, Tax Identification Number	58-1701987
Entity, Address, Address Line One	289 Great Road
Entity, Address, City or Town	Acton
Entity, Address, State or Province	MA
Entity, Address, Postal Zip Code	01720
City Area Code	978
Local Phone Number	206-8220
Title of 12(b) Security	Common stock. $0.005 par value
Trading Symbol	PMD
Security Exchange Name	NASDAQ
Entity, Well-known Seasoned Issuer	No
Entity, Voluntary Filers	No
Entity, Current Reporting Status	Yes
Entity, Interactive Data, Current	Yes
Entity, Filer Category	Non-accelerated Filer
Entity, Small Business	true
Entity, Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity, Shell Company	false
Entity, Public Float			$ 26.9
Entity, Common Stock Shares, Outstanding		5,684,647
Auditor Name	BDO USA, LLP
Auditor Location	Boston, Massachusetts
Auditor Firm ID	243
Amendment Description	On March 27, 2023 Psychemedics Corporation (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Original Form 10-K”). This Amendment No. 1 (the “Amendment”) amends Part II, Item 9B to correct an error in the description of the Change in Control Severance Agreement entered into on March 21, 2023 with Charles Doucot. It also amends Part III - EXECUTIVE COMPENSATION – Potential Payments upon Termination and Change in Control - to reflect a correction of amounts payable to Mr. Doucot. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, we have repeated in this Amendment the entire text of Item 9B of Part II and Part III - EXECUTIVE COMPENSATION – Potential Payments upon Termination and Change in Control - of the Original Filing in this Amendment and we have also repeated Part IV Item 15, Exhibits, Financial Statement Schedules in its entirety. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and our principal financial officer are filed as exhibits to this Amendment under Item 15 of Part IV hereof. Except as stated herein, this Amendment does not reflect events occurring after the filing of the Original Form 10-K with the Securities and Exchange Commission on March 27, 2023 and no attempt has been made in this Amendment to modify or update other disclosures as presented in the Original Form 10-K.
Amendment Flag	true
Entity, Central Index Key	0000806517

XML 10 pmd20230329_10ka_htm.xml IDEA: XBRL DOCUMENT 0000806517 2022-01-01 2022-12-31 0000806517 2022-06-30 0000806517 2023-03-15 iso4217:USD true 0000806517 10-K/A true 2022-12-31 --12-31 FY 2022 false 1-13738 PSYCHEMEDICS CORPORATION DE 58-1701987 289 Great Road Acton MA 01720 978 206-8220 Common stock. $0.005 par value PMD NASDAQ No No Yes Yes Non-accelerated Filer true false false false 26900000 5684647 BDO USA, LLP Boston, Massachusetts 243 On March 27, 2023 Psychemedics Corporation (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Original Form 10-K”). This Amendment No. 1 (the “Amendment”) amends Part II, Item 9B to correct an error in the description of the Change in Control Severance Agreement entered into on March 21, 2023 with Charles Doucot. It also amends Part III - EXECUTIVE COMPENSATION – Potential Payments upon Termination and Change in Control - to reflect a correction of amounts payable to Mr. Doucot. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, we have repeated in this Amendment the entire text of Item 9B of Part II and Part III - EXECUTIVE COMPENSATION – Potential Payments upon Termination and Change in Control - of the Original Filing in this Amendment and we have also repeated Part IV Item 15, Exhibits, Financial Statement Schedules in its entirety. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and our principal financial officer are filed as exhibits to this Amendment under Item 15 of Part IV hereof. Except as stated herein, this Amendment does not reflect events occurring after the filing of the Original Form 10-K with the Securities and Exchange Commission on March 27, 2023 and no attempt has been made in this Amendment to modify or update other disclosures as presented in the Original Form 10-K. EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 37 1 false 0 0 false 2 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.pmd.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports pmd20230329_10ka.htm ex_494493.htm ex_494494.htm ex_495196.htm pmd-20221231.xsd pmd-20221231_def.xml pmd-20221231_lab.xml pmd-20221231_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pmd20230329_10ka.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 37 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "pmd-20221231_def.xml" ] }, "inline": { "local": [ "pmd20230329_10ka.htm" ] }, "labelLink": { "local": [ "pmd-20221231_lab.xml" ] }, "presentationLink": { "local": [ "pmd-20221231_pre.xml" ] }, "schema": { "local": [ "pmd-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 41, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 37, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pmd", "nsuri": "http://www.pmd.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "pmd20230329_10ka.htm", "contextRef": "d202310KA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.pmd.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "pmd20230329_10ka.htm", "contextRef": "d202310KA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document, Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document, Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document, Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document, Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity, Common Stock Shares, Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity, Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity, Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity, Interactive Data, Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity, Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity, Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity, Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity, Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity, Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pmd.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" } }, "unitCount": 2 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001171843-23-002005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-002005-xbrl.zip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